Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 4, 2007, Pages 521-528

  Furuta, T ^a   Shirai, N ^a   Kodaira, M ^b   Sugimoto, M ^a   Nogaki, A ^b   Kuriyama, S ^b   Iwaizumi, M ^b   Yamade, M ^b   Terakawa, I ^b   Ohashi, K ^c   Ishizaki, T ^d   Hishida, A ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Yaizu Municipal Hospital   (Japan)

^c OITA UNIVERSITY   (Japan)

^d TEIKYO HEISEI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; RABEPRAZOLE; RIBOSOME RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOCHROME P450 2C19 GENE; DNA POLYMORPHISM; DRUG COST; DUODENUM ULCER; FEMALE; GASTRIC PH MONITORING; GASTRITIS; GASTRODUODENAL ULCER; GENE; GENETIC ANALYSIS; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STOMACH ULCER; TREATMENT DURATION; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CLARITHROMYCIN; COSTS AND COST ANALYSIS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RNA, RIBOSOMAL;

EID: 33947375710     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100043     Document Type: Article

References (46)

1. Wotherspoon, A.C. H. pylori infection and gastric lymphoma. Br. Med. Bull. 54, 79-85 (1998).
2. Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S. & Yamakido, M. et al. H. pylori infection and the development of gastric cancer. N. Engl. J. Med. 345, 784-789 (2001).
3. Marshall, B.J., Goodwin, C.S., Warren, J.R., Murray, R., Blincow, E.D. & Blackbourn, S.J. et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 2, 1437-1442 (1988).
4. Soll, A.H. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA 275, 622-629 (1996).
5. Malfertheiner, P., Megraud, F., O'Morain, C., Hungin, A.P., Jones, R. & Axon, A. et al. Current concepts in the management of H. pylori infection-the Maastricht 2-2000 Consensus Report. Aliment. Pharmacol. Ther. 16, 167-180 (2002).
6. Di Campli, C., Gasbarrini, A., Nucera, E., Franceschi, F., Ojetti, V. & Sanz Torre, E. et al. Beneficial effects of H. pylori eradication on idiopathic chronic urticaria. Dig. Dis. Sci. 43, 1226-1229 (1998).
7. Tohda, S. & Ohkusa, T. Resolution of refractory idiopathic thrombocytopenic purpura after eradication of H. pylori. Am. J. Hematol. 65, 329-330 (2000).
8. Annibale, B., Marignani, M., Monarca, B., Antonelli, G., Marcheggiano, A. & Martino, G. et al. Reversal of iron deficiency anemia after H. pylori eradication in patients with asymptomatic gastritis. Ann. Intern. Med. 131, 668-672 (1999).
9. Walsh, J.H. & Peterson, W.L. The treatment of H. pylori infection in the management of peptic ulcer disease. N. Engl. J. Med. 333, 984-991 (1995).
10. Lind, T., Megraud, F., Unge, P., Bayerdorffer, E., O'Morain, C. & Spiller, R. et al. The MACH2 study: role of omeprazole in eradication of H. pylori with 1-week triple therapies. Gastroenterology 11, 248-253 (1999).
11. Suerbaum, S. & Michetti, P. H. pylori infection. N. Engl. J. Med. 347, 1175-1186 (2002).
12. Sohn, D.R., Kwon, J.T., Kim, H.K. & Ishizaki, T. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status. Clin. Pharmacol. Ther. 61, 574-582 (1997).
13. Andersson, T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin. Pharmacokinet. 31, 9-28 (1996).
14. Chang, M., Tybring, G., Dahl, M.L., Gotharson, E., Sagar, M. & Seensalu, R. et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br. J. Clin. Pharmacol. 39, 511-518 (1995).
15. Chang, M., Dahl, M.L., Tybring, G., Gotharson, E. & Bertilsson, L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5, 358-363 (1995).
16. Ieiri, I., Mamiya, K., Urae, A., Wada, Y., Kimura, M. & Irie, S. et al. Stereoselective 4′-hydroxylation of phenytoin: relationship to (S)- mephenytoin polymorphism in Japanese. Br. J. Clin. Pharmacol. 43, 441-445 (1997).
17. Furuta, T., Ohashi, K., Kosuge, K., Zhao, X.J., Takashima, M. & Kimura, M. et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin. Pharmacol. Ther. 65, 552-561 (1999).
18. Shirai, N., Furuta, T., Moriyama, Y., Okochi, H., Kobayashi, K. & Takashima, M. et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol. Ther. 15, 1929-1937 (2001).
19. Wilkinson, G.R. Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 352, 2211-2221 (2005).
20. Schwab, M., Schaeffeler, E., Klotz, U. & Treiber, G. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of H. pylori. Clin. Pharmacol. Ther. 76, 201-209 (2004).
21. Sapone, A., Vaira, D., Trespidi, S., Perna, F., Gatta, L. & Tampieri, A. et al. The clinical role of cytochrome p450 genotypes in H. pylori management. Am. J. Gastroenterol. 98, 1010-1015 (2003).
22. Furuta, T., Shirai, N., Takashima, M., Xiao, F., Hanai, H. & Nakagawa, K. et al. Effects of genotypic differences in CYP2C19 status on cure rates for H. pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 11, 341-348 (2001).
23. Furuta, T., Ohashi, K., Kamata, T., Takashima, M., Kosuge, K. & Kawasaki, T. et al. Effect of genetic differences in omeprazole metabolism on cure rates for H. pylori infection and peptic ulcer. Ann. Intern. Med. 129, 1027-1030 (1998).
24. Megraud, F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 53, 1374-1384 (2004).
25. Murakami, K., Sato, R., Okimoto, T., Nasu, M., Fujioka, T. & Kodama, M. et al. Eradication rates of clarithromycin-resistant H. pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol. Ther. 16, 1933-1938 (2002).
26. Stone, G.G., Shortridge, D., Flamm, R.K., Versalovic, J., Beyer, J. & Idler, K. et al. Identification of a 23S rRNA gene mutation in clarithromycin-resistant H. pylori. Helicobacter 1, 227-228 (1996).
27. Versalovic, J., Shortridge, D., Kibler, K., Griffy, M.V., Beyer, J. & Flamm, R.K. et al. Mutations in 23S rRNA are associated with clarithromycin resistance in H. pylori. Antimicrob. Agents Chemother. 40, 477-480 (1996).
28. Stone, G.G., Shortridge, D., Versalovic, J., Beyer, J., Flamm, R.K. & Graham, D.Y. et al. A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant H. pylori. Antimicrob. Agents Chemother. 41, 712-714 (1997).
29. Taylor, D.E., Ge, Z., Purych, D., Lo, T. & Hiratsuka, K. Cloning and sequence analysis of two copies of a 23S rRNA gene from H. pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob. Agents Chemother. 41, 2621-2628 (1997).
30. Versalovic, J., Osato, M.S., Spakovsky, K., Dore, M.P., Reddy, R. & Stone, G.G. et al. Point mutations in the 23S rRNA gene of H. pylori associated with different levels of clarithromycin resistance. J. Antimicrob. Chemother. 40, 283-286 (1997).
31. Furuta, T., Shirai, N., Takashima, M., Xiao, F., Hanai, H. & Sugimura, H. et al. Effect of genotypic differences in CYP2C19 on cure rates for H. pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther. 69, 158-168 (2001).
32. Furuta, T., Shirai, N., Sugimoto, M., Ohashi, K. & Ishizaki, T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 5, 181-202 (2004).
33. Furuta, T., Sagehashi, Y., Shirai, N., Sugimoto, M., Nakamura, A. & Kodaira, M. et al. Influence of CYP2C19 polymorphism and H. pylori genotype determined from gastric tissue samples on response to triple therapy for H. pylori Infection. Clin. Gastroenterol. Hepatol. 3, 564-573 (2005).
34. Hall, J.G., Eis, P.S., Law, S.M., Reynaldo, L.P., Prudent, J.R. & Marshall, D.J. et al. Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction. Proc. Natl. Acad. Sci. USA 97, 8272-8277 (2000).
35. Furuta, T., Shirai, N., Xiao, F., Ohashi, K. & Ishizaki, T. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin. Pharmacol. Ther. 70, 484-492 (2001).
36. Sugimoto, M., Furuta, T., Shirai, N., Kajimura, M., Hishida, A. & Sakurai, M. et al. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin. Pharmacol. Ther. 76, 290-301 (2004).
37. Asaka, M., Sugiyama, T., Kato, M., Satoh, K., Kuwayama, H. & Fukuda, Y. et al. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of H. pylori in Japanese peptic ulcer patients. Helicobacter 6, 254-261 (2001).
38. Murakami, K., Sato, R., Okimoto, T., Nasu, M., Fujioka, T. & Kodama, M. et al. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line H. pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol. Ther. 17, 119-123 (2003).
39. Furuta, T., Shirai, N., Xiao, F., Takashima, M., Sugimoto, M. & Kajimura, M. et al. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 50, 2274-2278 (2003).
40. Miehlke, S., Kirsch, C., Schneider-Brachert, W., Haferland, C., Neumeyer, M. & Bastlein, E. et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of H. pylori resistant to both metronidazole and clarithromycin. Helicobacter 8, 310-319 (2003).
41. Erah, P.O., Goddard, A.F., Barrett, D.A., Shaw, P.N. & Spiller, R.C. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of H. pylori infection. J. Antimicrob. Chemother. 39, 5-12 (1997).
42. Nakamura, M., Spiller, R.C., Barrett, D.A., Wibawa, J.I., Kumagai, N. & Tsuchimoto, K. et al. Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and clarithromycin triple therapy. Helicobacter 8, 294-299 (2003).
43. Xie, H.G., Stein, C.M., Kim, R.B., Wilkinson, G.R., Flockhart, D.A. & Wood, A.J. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 9, 539-549 (1999).
44. Kubota, T., Chiba, K. & Ishizaki, T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther. 60, 661-666 (1996).
45. Chiba, N., Veldhuyzen Van Zanten, S.J., Escobedo, S., Grace, E., Lee, J. & Sinclair, P. et al. Economic evaluation of H. pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. Aliment Pharmacol. Ther. 19, 349-358 (2004).
46. Phillips, K.A. & Van Bebber, S.L. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics 5, 1139-1149 (2004).